首頁 > 市場調查報告書 > 醫療設備

體外診斷泌尿科

市場調查報告書

商品編碼

1495980

全球尿液檢查市場－2024年至2029年預測

Global Urinalysis Market - Forecasts from 2024 to 2029

出版日期: 2024年04月16日 | 出版商:

Knowledge Sourcing Intelligence | 英文 135 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計預測期內尿液檢查市場將以5.86%的年複合成長率成長，市場規模預計將從2022年的30.15億美元增至2029年的44.89億美元。

尿液檢查是尿液檢查，用於診斷和治療多種疾病，包括尿道感染(UTI)、腎臟疾病和糖尿病。尿液檢查可評估尿液的外觀、濃度和含量。如果您的尿液觀察異常，則懷疑患有某種疾病。 2021 年 9 月，Eurek Aert 報告稱，希望之城附屬機構轉化基因組學研究所 (TGen) 正在利用尿液檢查來分析尿液中的小鏈遊離 DNA，並找到了一種識別方法。現已開發出多種非侵入式自動化尿液分析儀，以提供快速、準確的檢測結果。

尿道結石、糖尿病、腎臟和肝臟疾病盛行率的增加、老年人口的增加以及與老齡化相關的疾病的增加正在推動市場擴張。醫院的加護病房和內外科病房的尿道結石、腎臟病和糖尿病等疾病的盛行率可能較高。根據國家生物技術資訊中心的數據，三分之一的女性會在 24 歲時患上尿道結石，一半的女性會在 32 歲時患上尿結石。

此外，根據國際糖尿病聯盟的數據，2019年約有4.63億年齡在20歲至79歲之間的人患有糖尿病，預計到2045年這一數字將增加至7億。此外，根據美國國家腎臟基金會的數據，慢性腎臟病(CKD) 影響著全球 10% 的人口，每年導致數百萬人死亡。

然而，嚴格的法律規範和不利的報銷條款可能會阻礙未來幾年的市場擴張。

市場促進因素：

預計老年人口的增加和與老齡化相關的疾病將擴大尿液檢查市場。

已開發國家和新興國家老年人口的增加將推動尿液檢查市場的成長。據世界衛生組織 (WHO) 稱，到 2020 年，60 歲以上的成年人將超過 5 歲以下的兒童。隨著老年人口的增加，糖尿病、腎臟和肝臟疾病等與老齡化相關的疾病的盛行率預計將急劇上升。

根據國際糖尿病組織的數據，65 歲以上的人中有五分之一患有糖尿病。由於對此類疾病的診斷和治療的增加，用於肌酸酐、白蛋白、葡萄糖、酮體和膽紅素等檢查的處方正在增加，這對用於執行這些檢查的尿液檢查有利。

市場限制因素：

不利的報銷條款可能會阻礙尿液檢查市場的發展。

市場成長的一個障礙是翻新設備的可用性，這些設備以較低的成本提供與新設備相同的功能。一些最終客戶（主要是中小型實驗室）正在選擇經濟高效的再生設備。尤其是在市場對價格敏感的新興國家，更喜歡具有類似功能的更便宜的設備。這可能會限制銷售品牌分析設備的公司的收益並抑制市場成長。

北美地區預計有很大的市場。

由於人口老化和慢性腎臟病的高盛行率，北美市場預計將佔據重要的市場地位。腎衰竭、高血壓和糖尿病都與 CKD 有關。根據美國國家腎臟基金會的數據，每年死於 CKD 的人數多於死於乳癌或攝護腺癌的人數。腎臟疾病是美國的首要死因。目前它影響著美國大約 3700 萬人。腎臟疾病在老年人中很常見，影響約 15% 的成年人口。

腎臟疾病影響約三分之一的糖尿病患者和大約五分之一的高血壓成年人。因此，對 CKD 的準確檢測和治療的需求不斷成長，這些因素可能會推動尿液檢查的需求。

主要發展

2023 年 12 月 - 西門子 Healthineers 推出了 Atellica UAS 60 分析儀，這是一種用於尿液沉渣分析的數位解決方案。這種自動化工具取代了手動顯微鏡，可以更快、更準確地審查和報告結果。每個樣本產生 15 張高解析度數位影像，並採用自動影像評估模組技術來自動識別顆粒、即時查看模式以可視化運動，以及自動細菌子分類以更輕鬆地識別 CKD 和尿道結石。
2022 年 11 月 - EmeritusDX 和 KDx Diagnostics Inc. 合作開發 URO17，這是一種用於膀胱癌檢測的非侵入性尿液檢查。 URO17 是一種高靈敏度和高陰性預測值 (NPV) 檢測，可確定活動性膀胱癌的狀態並改善患者診斷。 EmeritusDX 在美國作為臨床實驗室開發的測試提供，能夠向全國泌尿系統診所提供 URO17 測試。
2022 年 10 月 - IoMT 醫療科技新興企業Olive Diagnostics 的創新人工智慧尿液分析儀 Olive KG 獲得了歐洲 CE 標誌。該設備是世界上第一款免持、非侵入性、基於人工智慧的光學設備，可安裝在任何廁所中，實現被動、無縫尿液分析。它可以測量紅血球、蛋白質、亞硝酸鹽、pH值、尿量、尿壓、尿液顏色、排尿頻率等，無需使用者干涉即可對患者尿液中的重要參數進行高品質分析。該設備產生受 GDPR 和 HIPPA 要求保護的即時個人資料，這些數據會傳輸到雲端並由您的醫生進行處理。
2022 年 9 月 - Sysmex 公司宣布推出一款用於尿液沉渣檢測的新產品，全自動尿液顆粒分析儀 (UF-1500)。 UF-1500 繼承了 UF-5000 的功能和可操作性，同時更加緊湊。我們提供適合您環境的廣泛解決方案，並為中小型設施的尿液檢查的合理化和標準化做出貢獻。它還可以連接到尿液生化分析儀的傳輸系統，滿足各種客戶的需求，包括中小型設施和大型設施的備份系統的要求。

Urinalysis is a urine test that is used to diagnose and treat a variety of conditions, including urinary tract infections (UTI), kidney disease, and diabetes. During a urinalysis, the appearance, concentration, and content of urine are all evaluated. Abnormal urine findings may indicate a condition or illness. In September 2021, according to Eurek Aert, the Translational Genomics Research Institute (TGen), a City of Hope affiliate, discovered a method to pinpoint early-stage cancer by utilizing Urinalysis to analyze small strands of cell-free DNA in urine. Various non-invasive urine automated analyzers have been developed to provide rapid and accurate test results.

The increased prevalence of UTIs, diabetes, and kidney and liver disorders, as well as the growing geriatric population and the resulting increase in age-related diseases, are driving market expansion. In hospitals and other critical care units and medical-surgical units, the prevalence of conditions such as UTI, renal disease, and diabetes is likely to be greater. According to the National Centre of Biotechnology Information, one-third of women will have experienced a UTI by the age of 24 and half by the age of 32.

Additionally, according to the International Diabetes Federation, about 463 million individuals between the age of 20-79 years had diabetes in 2019, and this number is expected to grow to 700 million by 2045. Furthermore, according to the National Kidney Foundation, chronic kidney disease (CKD) affects 10% of the world's population, with millions dying each year.

However, the market expansion is likely to be hampered in the coming years by a strict regulatory framework and an unfavorable reimbursement condition.

Market Drivers:

Rising geriatric population and age-related diseases are anticipated to increase the global urinalysis market.

The growing geriatric population in developed and developing countries will boost the urinalysis market growth. According to the World Health Organization, the number of adults aged 60 and more will surpass children under the age of five by 2020. The prevalence of age-related diseases such as diabetes and kidney and liver disease is projected to rise dramatically as the geriatric population grows.

According to the International Diabetes Organization, one in every five persons over the age of 65 has diabetes. Prescriptions for tests such as creatinine, albumin, glucose, ketones, and bilirubin, among others, are on the rise as a result of the increased diagnosis and treatment of such disorders, which is benefiting urinalysis, which is used to perform these tests.

Market Restraints:

Unfavorable reimbursement conditions could hamper the global urinalysis market.

The availability of refurbished instruments, which provide the same functionality as new equipment at a cheaper cost, poses a barrier to market growth. Several end customers, primarily small and medium-sized laboratories, choose cost-effective reconditioned equipment. Particularly in developing nations, where markets are price-sensitive, inexpensive instruments with equivalent functions are preferred. This is likely to limit the revenue of companies that sell branded analyzers, thus limiting the market growth.

The North American region is projected to have a significant marketplace.

Due to an aging population and a high prevalence of CKD, the North American market is projected to have a significant market position. Kidney failure, high blood pressure, and diabetes are all linked to CKD. According to the National Kidney Foundation, more people die due to CKD than breast cancer and prostate cancer each year. In the United States, kidney disease is a major cause of death. It now affects around 37 million individuals in the US. It is more common in the aging population, affecting around 15% of the adult population.

Kidney disease affects around one in every three individuals with diabetes and one in every five adults with high blood pressure. Hence, there is a growing demand for accurate detection and treatment of CKD, and these factors are likely to drive up demand for urinalysis.

Key Developments:

December 2023- Siemens Healthineers introduced the Atellica UAS 60 Analyzer, a digital solution for urine sediment analysis. This automated tool replaces manual microscopy, enabling quicker and more accurate results review and reporting. It generates 15 high-resolution digital images per sample, features auto Image Evaluation Module technology for automatic identification of particles, live-view mode for movement visualization, and automatic bacterial subcategorization for easier identification of CKD and UTI.
November 2022- EmeritusDX and KDx Diagnostics Inc. partnered to offer the URO17 non-invasive urine test for bladder cancer detection. URO17 is a highly sensitive and negative predicted value (NPV) test that can determine the status of active bladder cancer and improve patient diagnosis. It is available as a Laboratory Developed Test in the US, allowing EmeritusDX to offer URO17 testing to Urology practices nationwide. The test can rule out patients with micro-hematuria for unnecessary cystoscopy and reduce the work-up.
October 2022- Olive Diagnostics, an IoMT MedTech startup, received the European CE Mark for its innovative AI-based urine analysis device, the Olive KG. The device is the world's first hands-free, non-invasive, AI-based optical device for passive and seamless urinalysis mounted on any toilet. It performs high-quality analysis of important parameters in patients' urine without user intervention, measuring red blood cells, proteins, Nitrites, pH levels, volume, pressure, color, and frequency of urination. The device generates real-time personal data, secured according to GDPR and HIPPA requirements, which is sent to the cloud and treated by the treating physician.
September 2022- Sysmex Corporation introduced the UF-1500 Fully Automated Urine Particle Analyzer (UF-1500), a new product for urine sediment testing. The UF-1500 inherits the functionality and usability of the UF-5000 model but is downsized. It offers a wider range of solutions tailored to customers' environments and contributes to streamlining and standardization of urine testing at small and medium-sized facilities. The UF-1500 supports connectivity with transportation systems for urine chemistry analyzers, meeting various customer needs, including demand from small and medium-sized facilities and backup systems from large facilities.

Market Segmentation:

By Product Type

Instruments
Automated Urine Analyzer
Semi-automated Urine Analyzer
Point-of-Care Urine Analyzer
Consumables
Reagents
Kits
Dipsticks
Disposables

By Test Type

Biochemical Urinalysis
Pregnancy & Fertility Urinalysis
Sediment Urinalysis

By Application

Urinary Tract Infections
Diabetes
Kidney Diseases
Liver Diseases
Pregnancy and Fertility
Others

By End-User

Hospitals & Clinics
Diagnostic Laboratories
Research & Academic Institutions
Home Care Settings

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
UK
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
South Africa
Others
Asia Pacific
China
India
Japan
South Korea
Taiwan
Thailand
Indonesia
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View

5. GLOBAL URINALYSIS MARKET BY PRODUCT TYPE

5.1. Introduction
5.2. Instruments
- 5.2.1. Market Opportunities and Trends
- 5.2.2. Growth Prospects
- 5.2.3. Geographic Lucrativeness
- 5.2.4. Automated Urine Analyzer
- 5.2.5. Semi-automated Urine Analyzer
- 5.2.6. Point-of-Care Urine Analyzer
5.3. Consumables
- 5.3.1. Market Opportunities and Trends
- 5.3.2. Growth Prospects
- 5.3.3. Geographic Lucrativeness
- 5.3.4. Reagents
- 5.3.5. Kits
- 5.3.6. Dipsticks
- 5.3.7. Disposables

6. GLOBAL URINALYSIS MARKET BY TEST TYPE

6.1. Introduction
6.2. Biochemical Urinalysis
- 6.2.1. Market Opportunities and Trends
- 6.2.2. Growth Prospects
- 6.2.3. Geographic Lucrativeness
6.3. Pregnancy & Fertility Urinalysis
- 6.3.1. Market Opportunities and Trends
- 6.3.2. Growth Prospects
- 6.3.3. Geographic Lucrativeness
6.4. Sediment Urinalysis
- 6.4.1. Market Opportunities and Trends
- 6.4.2. Growth Prospects
- 6.4.3. Geographic Lucrativeness

7. GLOBAL URINALYSIS MARKET BY APPLICATION

7.1. Introduction
7.2. Urinary Tract Infections
- 7.2.1. Market Opportunities and Trends
- 7.2.2. Growth Prospects
- 7.2.3. Geographic Lucrativeness
7.3. Diabetes
- 7.3.1. Market Opportunities and Trends
- 7.3.2. Growth Prospects
- 7.3.3. Geographic Lucrativeness
7.4. Kidney Diseases
- 7.4.1. Market Opportunities and Trends
- 7.4.2. Growth Prospects
- 7.4.3. Geographic Lucrativeness
7.5. Liver Diseases
- 7.5.1. Market Opportunities and Trends
- 7.5.2. Growth Prospects
- 7.5.3. Geographic Lucrativeness
7.6. Pregnancy and Fertility
- 7.6.1. Market Opportunities and Trends
- 7.6.2. Growth Prospects
- 7.6.3. Geographic Lucrativeness
7.7. Others
- 7.7.1. Market Opportunities and Trends
- 7.7.2. Growth Prospects
- 7.7.3. Geographic Lucrativeness

8. GLOBAL URINALYSIS MARKET BY END-USER

8.1. Introduction
8.2. Hospitals & Clinics
- 8.2.1. Market Opportunities and Trends
- 8.2.2. Growth Prospects
- 8.2.3. Geographic Lucrativeness
8.3. Diagnostic Laboratories
- 8.3.1. Market Opportunities and Trends
- 8.3.2. Growth Prospects
- 8.3.3. Geographic Lucrativeness
8.4. Research & Academic Institutions
- 8.4.1. Market Opportunities and Trends
- 8.4.2. Growth Prospects
- 8.4.3. Geographic Lucrativeness
8.5. Home Care Settings
- 8.5.1. Market Opportunities and Trends
- 8.5.2. Growth Prospects
- 8.5.3. Geographic Lucrativeness

9. GLOBAL URINALYSIS MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. By Product Type
- 9.2.2. By Test Type
- 9.2.3. By Application
- 9.2.4. By End-User
- 9.2.5. By Country
  - 9.2.5.1. USA
    - 9.2.5.1.1. Market Opportunities and Trends
    - 9.2.5.1.2. Growth Prospects
  - 9.2.5.2. Canada
    - 9.2.5.2.1. Market Opportunities and Trends
    - 9.2.5.2.2. Growth Prospects
  - 9.2.5.3. Mexico
    - 9.2.5.3.1. Market Opportunities and Trends
    - 9.2.5.3.2. Growth Prospects
9.3. South America
- 9.3.1. By Product Type
- 9.3.2. By Test Type
- 9.3.3. By Application
- 9.3.4. By End-User
- 9.3.5. By Country
  - 9.3.5.1. Brazil
    - 9.3.5.1.1. Market Opportunities and Trends
    - 9.3.5.1.2. Growth Prospects
  - 9.3.5.2. Argentina
    - 9.3.5.2.1. Market Opportunities and Trends
    - 9.3.5.2.2. Growth Prospects
  - 9.3.5.3. Others
    - 9.3.5.3.1. Market Opportunities and Trends
    - 9.3.5.3.2. Growth Prospects
9.4. Europe
- 9.4.1. By Product Type
- 9.4.2. By Test Type
- 9.4.3. By Application
- 9.4.4. By End-User
- 9.4.5. By Country
  - 9.4.5.1. Germany
    - 9.4.5.1.1. Market Opportunities and Trends
    - 9.4.5.1.2. Growth Prospects
  - 9.4.5.2. France
    - 9.4.5.2.1. Market Opportunities and Trends
    - 9.4.5.2.2. Growth Prospects
  - 9.4.5.3. UK
    - 9.4.5.3.1. Market Opportunities and Trends
    - 9.4.5.3.2. Growth Prospects
  - 9.4.5.4. Italy
    - 9.4.5.4.1. Market Opportunities and Trends
    - 9.4.5.4.2. Growth Prospects
  - 9.4.5.5. Spain
    - 9.4.5.5.1. Market Opportunities and Trends
    - 9.4.5.5.2. Growth Prospects
  - 9.4.5.6. Others
    - 9.4.5.6.1. Market Opportunities and Trends
    - 9.4.5.6.2. Growth Prospects
9.5. Middle East and Africa
- 9.5.1. By Product Type
- 9.5.2. By Test Type
- 9.5.3. By Application
- 9.5.4. By End-User
- 9.5.5. By Country
  - 9.5.5.1. Saudi Arabia
    - 9.5.5.1.1. Market Opportunities and Trends
    - 9.5.5.1.2. Growth Prospects
  - 9.5.5.2. UAE
    - 9.5.5.2.1. Market Opportunities and Trends
    - 9.5.5.2.2. Growth Prospects
  - 9.5.5.3. South Africa
    - 9.5.5.3.1. Market Opportunities and Trends
    - 9.5.5.3.2. Growth Prospects
  - 9.5.5.4. Others
    - 9.5.5.4.1. Market Opportunities and Trends
    - 9.5.5.4.2. Growth Prospects
9.6. Asia Pacific
- 9.6.1. By Product Type
- 9.6.2. By Test Type
- 9.6.3. By Application
- 9.6.4. By End-User
- 9.6.5. By Country
  - 9.6.5.1. China
    - 9.6.5.1.1. Market Opportunities and Trends
    - 9.6.5.1.2. Growth Prospects
  - 9.6.5.2. India
    - 9.6.5.2.1. Market Opportunities and Trends
    - 9.6.5.2.2. Growth Prospects
  - 9.6.5.3. Japan
    - 9.6.5.3.1. Market Opportunities and Trends
    - 9.6.5.3.2. Growth Prospects
  - 9.6.5.4. South Korea
    - 9.6.5.4.1. Market Opportunities and Trends
    - 9.6.5.4.2. Growth Prospects
  - 9.6.5.5. Taiwan
    - 9.6.5.5.1. Market Opportunities and Trends
    - 9.6.5.5.2. Growth Prospects
  - 9.6.5.6. Thailand
    - 9.6.5.6.1. Market Opportunities and Trends
    - 9.6.5.6.2. Growth Prospects
  - 9.6.5.7. Indonesia
    - 9.6.5.7.1. Market Opportunities and Trends
    - 9.6.5.7.2. Growth Prospects
  - 9.6.5.8. Others
    - 9.6.5.8.1. Market Opportunities and Trends
    - 9.6.5.8.2. Growth Prospects